Jean Bousquet

Summary

Country: France

Publications

  1. ncbi request reprint Natural rubber latex allergy among health care workers: a systematic review of the evidence
    Jean Bousquet
    Service des Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, University Hospital, 34295 Montpellier Cedex 5, France
    J Allergy Clin Immunol 118:447-54. 2006
  2. ncbi request reprint Specific immunotherapy in rhinitis and asthma
    J Bousquet
    Service des Maladies Respiratoires, INSERM U454 Hĵpital Arnaud de Villeneuve, Montepelier, France
    Ann Allergy Asthma Immunol 87:38-42. 2001
  3. ncbi request reprint Modulite((R)) technology in the development of formoterol HFA pMDI: clinical evidence and future opportunities
    Jean Bousquet
    , avenue du Doyen Gaston Giraud, FR 34000, Montpellier, France
    Expert Rev Respir Med 2:27-36. 2008
  4. ncbi request reprint Prospects for a vaccine in allergic diseases and asthma
    J Bousquet
    Hopital Arnaud de Villeneuve, INSERM V454, Montpellier, France
    BioDrugs 13:61-75. 2000
  5. ncbi request reprint A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients
    J Bousquet
    Hopital Arnaud de Villeneuve, Montpellier, France
    Respiration 72:6-12. 2005
  6. ncbi request reprint Characteristics of patients with seasonal allergic rhinitis and concomitant asthma
    J Bousquet
    Montpellier University INSERM, Montpellier, France
    Clin Exp Allergy 34:897-903. 2004
  7. ncbi request reprint [Recommendations for the management of asthma]
    J Bousquet
    Service des Maladies Respiratoires, CHU Monptellier, INSERM U454, Hôpital Arnaud de Villeneuve 34 295 Montpellier
    Rev Prat 51:533-7. 2001
  8. ncbi request reprint [Nasal allergy and asthma: one or two diseases?]
    Pascal Demoly
    Maladies Respiratoires, INSERM U454, IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier cedex 05
    Bull Acad Natl Med 189:1461-73. 2005
  9. ncbi request reprint A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) a
    J Bousquet
    Hopital Arnaud de Villeneuve, Montpellier, France
    Respiration 72:13-9. 2005
  10. doi request reprint How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement
    Jean Bousquet
    University Hospital, Hopital Arnaud de Villeneuve, Montpellier, France
    Allergy 66:765-74. 2011

Detail Information

Publications143 found, 100 shown here

  1. ncbi request reprint Natural rubber latex allergy among health care workers: a systematic review of the evidence
    Jean Bousquet
    Service des Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, University Hospital, 34295 Montpellier Cedex 5, France
    J Allergy Clin Immunol 118:447-54. 2006
    ..Natural rubber latex is a recognized allergen, but a recent meta-analysis failed to find any association between latex exposure and allergy in health care workers (HCWs)...
  2. ncbi request reprint Specific immunotherapy in rhinitis and asthma
    J Bousquet
    Service des Maladies Respiratoires, INSERM U454 Hĵpital Arnaud de Villeneuve, Montepelier, France
    Ann Allergy Asthma Immunol 87:38-42. 2001
    ....
  3. ncbi request reprint Modulite((R)) technology in the development of formoterol HFA pMDI: clinical evidence and future opportunities
    Jean Bousquet
    , avenue du Doyen Gaston Giraud, FR 34000, Montpellier, France
    Expert Rev Respir Med 2:27-36. 2008
    ..Therefore, the Modulite formoterol hydrofluoroalkane-based formulation in extra-fine particles is a valuable therapeutic option for both patients and physicians in the management of asthma and chronic obstructive pulmonary disease...
  4. ncbi request reprint Prospects for a vaccine in allergic diseases and asthma
    J Bousquet
    Hopital Arnaud de Villeneuve, INSERM V454, Montpellier, France
    BioDrugs 13:61-75. 2000
    ..Nonspecific approaches include humanised anti-IgE antibodies,moderation of the T(H)2 cytokine network and antisense oligodeoxynucleotide therapy...
  5. ncbi request reprint A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients
    J Bousquet
    Hopital Arnaud de Villeneuve, Montpellier, France
    Respiration 72:6-12. 2005
    ..Formoterol fumarate has been recently formulated in an HFA-134a-containing pMDI and is undergoing clinical testing with the aim of providing an effective, safe and environmentally-friendly alternative to currently existing formulations...
  6. ncbi request reprint Characteristics of patients with seasonal allergic rhinitis and concomitant asthma
    J Bousquet
    Montpellier University INSERM, Montpellier, France
    Clin Exp Allergy 34:897-903. 2004
    ....
  7. ncbi request reprint [Recommendations for the management of asthma]
    J Bousquet
    Service des Maladies Respiratoires, CHU Monptellier, INSERM U454, Hôpital Arnaud de Villeneuve 34 295 Montpellier
    Rev Prat 51:533-7. 2001
    ..These guidelines are applied in over 100 countries worldwide, and, in countries where they are applied, morbidity and mortality due to asthma have decreased...
  8. ncbi request reprint [Nasal allergy and asthma: one or two diseases?]
    Pascal Demoly
    Maladies Respiratoires, INSERM U454, IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier cedex 05
    Bull Acad Natl Med 189:1461-73. 2005
    ....
  9. ncbi request reprint A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) a
    J Bousquet
    Hopital Arnaud de Villeneuve, Montpellier, France
    Respiration 72:13-9. 2005
    ..These formulations contain hydrofluoroalkanes (HFAs) in redesigned metered-dose inhalers...
  10. doi request reprint How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement
    Jean Bousquet
    University Hospital, Hopital Arnaud de Villeneuve, Montpellier, France
    Allergy 66:765-74. 2011
    ..It also provides some suggestions for the research that will be needed. Interestingly, some of the research questions can be approached with the available data obtained from large RCTs...
  11. ncbi request reprint Rapid effects of dexamethasone on intracellular pH and Na+/H+ exchanger activity in human bronchial epithelial cells
    Valia A Verrière
    INSERM U454, Centre Hospitalier Universitaire Arnaud de Villeneuve, 34295 Montpellier, France
    J Biol Chem 280:35807-14. 2005
    ....
  12. ncbi request reprint Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound
    Isabelle Vachier
    Clinique des Maladies Respiratoires, CHU, Montpellier, France
    J Allergy Clin Immunol 115:55-60. 2005
    ..They are produced by different enzymatic pathways. Patients with severe asthma present ongoing airway inflammation despite chronic long-term treatment including oral glucocorticoids...
  13. ncbi request reprint Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone
    Jean Bousquet
    Hopital Arnaud de Villeneuve, 371 Avenue Doyen Gaston Giraud, FR 34000 Montpellier, France
    Respir Med 101:2437-46. 2007
    ....
  14. ncbi request reprint Clinical studies in asthmatics with a new non-extra fine HFA formulation of beclometasone dipropionate (BDP Modulite)
    J Bousquet
    Hopital Arnaud de Villeneuve, Montpellier, France
    Respir Med 96:S17-27. 2002
    ..In conclusion, the results of the clinical studies with BDP Modulite show that this new HFA formulation allows a seamless transition to CFC-free BDP, thus simplifying the changeover...
  15. doi request reprint Impact of allergic rhinitis symptoms on quality of life in primary care
    Philippe Jean Bousquet
    University Hospital, CHU de Montpellier, Montpellier, France
    Int Arch Allergy Immunol 160:393-400. 2013
    ..Allergic rhinitis (AR) impairs quality of life (QoL), sleep and work. The Allergic Rhinitis and its Impact on Asthma (ARIA) classification is widely used, but the impact of the different symptoms on QoL is not clear...
  16. doi request reprint Unmet needs in severe chronic upper airway disease (SCUAD)
    Jean Bousquet
    University Hospital, Montpellier, France
    J Allergy Clin Immunol 124:428-33. 2009
    ..This document can also serve to optimize the pharmacoeconomic evaluation of SCUADs by means of comparison with mild chronic upper airway diseases...
  17. ncbi request reprint Effects of inhaled corticosteroids on pathology in asthma and chronic obstructive pulmonary disease
    Pascal Chanez
    Clinique des Maladies Respiratoires, Hopital Arnaud de Villeneuve, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
    Proc Am Thorac Soc 1:184-90. 2004
    ..The effects of these drugs on structural changes in COPD have not been investigated extensively. Long-term prospective studies are needed to demonstrate the potential for ICSs to affect the natural history of chronic bronchial diseases...
  18. ncbi request reprint Lipoxin A4 stimulates a cytosolic Ca2+ increase in human bronchial epithelium
    Caroline Bonnans
    INSERM U454, Department of Respiratory Disease, Centre Hospitalier Universitaire Arnaud de Villeneuve, 34295 Montpellier cedex 05, France
    J Biol Chem 278:10879-84. 2003
    ....
  19. ncbi request reprint Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma
    J Bousquet
    Hopital Arnaud de Villeneuve, Montpellier, France
    Allergy 61:72-8. 2006
    ..Roflumilast is an oral, once-daily phosphodiesterase 4 inhibitor with anti-inflammatory activity in development for the treatment of asthma. Roflumilast was compared with inhaled beclomethasone dipropionate (BDP) in patients with asthma...
  20. doi request reprint Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review
    Jean Bousquet
    University Hospital, Department of Respiratory Diseases, Hopital Arnaud de Villeneuve, Montpellier, France
    Curr Med Res Opin 28:131-9. 2012
    ..Several criteria should be met by oral H(1)-antihistamines in terms of their pharmacological, and clinical efficacy and safety profiles...
  21. doi request reprint Efficacy of desloratadine in persistent allergic rhinitis - a GA²LEN study
    Jean Bousquet
    University Hospital, Hopital Arnaud de Villeneuve, Montpellier, France
    Int Arch Allergy Immunol 153:395-402. 2010
    ..There had been no placebo-controlled, randomized, clinical trial of desloratadine (DL) in patients with persistent allergic rhinitis to date...
  22. doi request reprint Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination
    Jean Bousquet
    University of Montpellier, Montpellier, France
    Clin Pharmacokinet 48:347-58. 2009
    ....
  23. doi request reprint The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article
    Philippe J Bousquet
    Department of Respiratory Diseases, University Hospital of Montpellier, Montpellier, France
    J Allergy Clin Immunol 127:49-56, 56.e1-11. 2011
    ..Randomized trials provide evidence to inform treatment decisions. The Consolidated Standards of Reporting Trials (CONSORT) Statement is a set of recommendations for the reporting of trials...
  24. ncbi request reprint Effects of glucocorticoids on endogenous and transcellular metabolism of eicosanoids in asthma
    I Vachier
    Clinique des Maladies Respiratoires, CHU-Montpellier INSERM U454, , Montpellier, France
    J Allergy Clin Immunol 107:824-31. 2001
    ..This study also questions the site of action of glucocorticoids in regulating the availability of arachidonic acid and potential eicosanoid regulation, as previously held in phospholipase A2 studies...
  25. ncbi request reprint High levels of urinary leukotriene E4 excretion in steroid treated patients with severe asthma
    Isabelle Vachier
    Clinique des Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, 371 Av du Doyen Gaston Giraud, 34295 Montpellier 5, France
    Respir Med 97:1225-9. 2003
    ..The findings support previous indications that one important component in asthmatic airway inflammation, the cysteinyl-leukotriene pathway remains relatively unopposed by oral glucocorticoids...
  26. doi request reprint Implementation of guidelines for allergic rhinitis in specialist practices. A randomized pragmatic controlled trial
    Jean Bousquet
    University Hospital and INSERM U780, Montpellier, France
    Int Arch Allergy Immunol 150:75-82. 2009
    ..Guidelines for allergic rhinitis are more effective than free-treatment choice in the control of seasonal allergic rhinitis...
  27. ncbi request reprint The response of two different dosages of beclometasone dipropionate suspension for nebulization versus a standard dose of beclometasone dipropionate via a metered-dose inhaler on bronchoprovocation testing in adults with asthma
    J Bousquet
    Hopital Arnaud de Villeneuve, Montpellier, France
    Respir Med 97:S11-4. 2003
    ..All treatments were comparable. All treatments were equally well tolerated. No significant effects on cortisol levels were reported in any of the treatment groups...
  28. ncbi request reprint Usefulness of bronchoalveolar lavage in asthmatics. The right clinical practice
    F B Michel
    Clinique des Maladies Respiratoires, Hôpital Aiguelongue, Montpellier, France
    Int Arch Allergy Appl Immunol 88:101-7. 1989
    ..BAL offers a new approach to the understanding of asthma. There is a lot of unresolved questions which should encourage us to exploit its potential to the full...
  29. doi request reprint Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis
    Philippe Jean Bousquet
    Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier, France
    J Allergy Clin Immunol 123:1349-54. 2009
    ..Most patients with allergic rhinitis consult in primary care. A simple test is needed to evaluate globally the severity of allergic rhinitis to assess the efficacy of treatment...
  30. ncbi request reprint Lipoxins are potential endogenous antiinflammatory mediators in asthma
    Caroline Bonnans
    Clinique des Maladies Respiratoires, INSERM U454 IFR 3, CHU, Montpellier, France
    Am J Respir Crit Care Med 165:1531-5. 2002
    ..Moreover, pertussis toxin reversed LXA4- and LXB4-inhibited IL-8 release. These findings suggest that lipoxins have potential antiinflammatory action in asthma...
  31. ncbi request reprint Immunotherapy: clinical trials--optimal trial and clinical outcomes
    Philippe Jean Bousquet
    Clinique des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Centre Hospitalier Universitaire, Montpellier, France
    Curr Opin Allergy Clin Immunol 7:561-6. 2007
    ..Although specific immunotherapy was introduced a century ago, very few trials meet the criteria for pivotal studies. The paper reviews the methods which should be used to investigate specific immunotherapy...
  32. pmc The public health implications of asthma
    Jean Bousquet
    Clinique des Maladies Respiratoires, Hopital Arnaud de Villeneuve, CHU Montpellier, 34295 Montpellier cedex 05, France
    Bull World Health Organ 83:548-54. 2005
    ..This paper presents a discussion of the burden of asthma and its socioeconomic implications and proposes a model to predict the costs incurred by the disease...
  33. doi request reprint Montelukast in guidelines and beyond
    Jean Bousquet
    Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, 371 Avenue Doyen Gaston Giraud, 34275 Montpellier, Cedex 5, France
    Adv Ther 26:575-87. 2009
    ..This review includes new studies that have not yet been considered in guidelines...
  34. doi request reprint Effect of smoking on symptoms of allergic rhinitis
    Philippe J Bousquet
    University Hospital and INSERM U780, Montpellier, France
    Ann Allergy Asthma Immunol 103:195-200. 2009
    ..Tobacco smoking is common in patients with allergic rhinitis...
  35. ncbi request reprint [GARD (Global Alliance against chronic Respiratory Diseases)]
    J Bousquet
    Hopital Arnaud de Villeneuve, Montpellier, France
    Rev Mal Respir 23:10S73-10S75. 2006
  36. ncbi request reprint Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group
    J Bousquet
    University Hospital and INSERM U454, Montpellier, France
    Clin Exp Allergy 35:728-32. 2005
    ..In the Allergic Rhinitis and its Impact on Asthma (ARIA) classification, intermittent and persistent rhinitis were proposed to replace seasonal and perennial allergic rhinitis (AR)...
  37. doi request reprint Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma
    J Bousquet
    Clinique des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Centre Hospitalier Universitaire, Montpellier Cedex, France
    Int J Clin Pract 63:806-19. 2009
    ..Future developments include the combination of MF with the long-acting bronchodilators, formoterol and indacaterol, to provide additional options in the treatment of asthma...
  38. ncbi request reprint Biologics in asthma: difficulties and drawbacks
    Jean Bousquet
    Hopital Arnaud de Villeneuve, Service des Maladies Respiratoires, 34295 Montpellier, Cedex 05, France
    Expert Opin Biol Ther 8:1921-8. 2008
    ..Biologics have become an increasingly important class of therapeutic compounds in a variety of immune and/or inflammatory diseases. Patients with severe uncontrolled asthma represent a significant unmet need...
  39. ncbi request reprint Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma
    Jean Bousquet
    Service de Pneumologie, Hopital Arnaud de Villeneuve, Montpellier, France
    Chest 125:1378-86. 2004
    ..To determine baseline characteristics predictive of response to omalizumab, an anti-IgE antibody, in patients with allergic asthma...
  40. doi request reprint Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper
    Jean Bousquet
    University Hospital, Hopital Arnaud de Villeneuve, Montpellier Cedex 5, France
    Allergy 65:1212-21. 2010
    ..Guidelines must be updated as new management options become available or important new evidence emerges. Transparent reporting of guidelines facilitates understanding and acceptance, but implementation strategies need to be improved...
  41. ncbi request reprint Passive and active smoking and exhaled nitric oxide levels according to asthma and atopy in adults
    Rachel Nadif
    INSERM, CESP Centre for research in Epidemiology and Population Health, Respiratory and Environmental Epidemiology Team U1018, Villejuif, France
    Ann Allergy Asthma Immunol 104:385-93. 2010
    ..No data are available regarding the utility of fractional exhaled nitric oxide (FeNO) level in guiding therapy in smoking asthmatic patients. Identification of the effect of smoking in a large sample is needed...
  42. pmc Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey
    Mahmoud Zureik
    European Community Respiratory Health Survey, Unit 408 Epidémiologie, Faculte de Medecine Xavier Bichat, BP 416, 75870 Paris Cedex 18, France
    BMJ 325:411-4. 2002
    ..To assess whether the severity of asthma is associated with sensitisation to airborne moulds rather than to other seasonal or perennial allergens...
  43. ncbi request reprint Epidemiologic study of the genetics and environment of asthma, bronchial hyperresponsiveness, and atopy
    Francine Kauffmann
    Epidemiology and Biostatistics, Institut National de la Santé et de la Recherche Médicale INSERM U472, Villejuif, France
    Chest 121:27S. 2002
  44. ncbi request reprint The relation between asthma and allergic rhinitis
    Pascal Demoly
    Exploration des Allergies Maladies Respiratoires INSERM U454, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Lancet 368:711-3. 2006
  45. ncbi request reprint Generation of eicosanoids from 15(S)-hydroxyeicosatetraenoic acid in blood monocytes from steroid-dependent asthmatic patients
    C Chavis
    INSERM U 454 IFR 3, Hopital Arnaud de Villeneuve, Montpellier, France
    Biochem Pharmacol 56:535-41. 1998
    ..02). This work shows for the first time that human PBM are able to metabolize 15(S)-HETE and lead to lipoxins and to an unknown metabolite, with the amounts of the latter being enhanced by long-term corticosteroid treatment...
  46. ncbi request reprint Rapid anti-secretory effects of glucocorticoids in human airway epithelium
    V Urbach
    INSERM U454, Centre Hospitalier Universitaire Arnaud de Villeneuve, Montpellier, France
    Steroids 71:323-8. 2006
    ....
  47. pmc Inflammatory features of nasal mucosa in smokers with and without COPD
    I Vachier
    Clinique des Maladies Respiratoires and U 454 INSERM, Hopital Arnaud de Villeneuve, Montpellier, France
    Thorax 59:303-7. 2004
    ....
  48. ncbi request reprint Genome screen in the French EGEA study: detection of linked regions shared or not shared by allergic rhinitis and asthma
    M H Dizier
    INSERM U535, Hopital Paul Brousse, Bâtiment Leriche, Villejuif Cedex, France
    Genes Immun 6:95-102. 2005
    ..While 1p31 may contain a genetic determinant common to asthma and AR, 2q32, 3p24-p14, 9p22 and 9q22-q34 are more likely to harbor genetic factors specific to AR...
  49. ncbi request reprint Quality of life in allergic rhinitis and asthma. A population-based study of young adults
    B Leynaert
    INSERM Unité 408, Paris, France
    Am J Respir Crit Care Med 162:1391-6. 2000
    ....
  50. ncbi request reprint [Allergy to macrolide antibiotics. Review of the literature]
    P Demoly
    INSERM U454 IFR3, Hôpital Amaud de Villeneuve, CHU de Montpellier
    Presse Med 29:321-6. 2000
    ..It would appear that macrolide allergies are unlikely to be class allergies. This is important as eviction advice could be limited to the single causal macrolide...
  51. ncbi request reprint [Drug allergies: management and current aspects]
    P Demoly
    Clinique des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier
    Presse Med 27:1406-11. 1998
    ..Allergic reactions are unpredictable reactions related to immunologic mechanism. Pseudoallergic reactions mimic allergic reactions but no drug-specific antibody or T cell proliferation can be demonstrated...
  52. ncbi request reprint Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]
    J Bousquet
    Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier, Cedex 5, France
    Clin Exp Allergy 35:723-7. 2005
    ..We assessed asthma-related medical resource use and attacks in asthmatic patients who did and did not have concomitant AR and were adding montelukast or salmeterol to baseline treatment with inhaled fluticasone...
  53. ncbi request reprint [Allergy to macrolides. 21 cases]
    P Demoly
    Maladies Respiratoires, Hôpital Amaud de Villeneuve, Montpellier
    Presse Med 29:294-8. 2000
    ..Allergic drug reactions to macrolides are extremely rare and there is little information in the literature concerning relevant diagnostic tests...
  54. ncbi request reprint Genome screen for asthma and related phenotypes in the French EGEA study
    M H Dizier
    INSERM U155, Universite Paris 7, Paris, France INSERM EPI 00 06, H opital St Louis, Paris, France
    Am J Respir Crit Care Med 162:1812-8. 2000
    ..005), 12q24 (p = 0.0008), and 17q12-21 (p = 0.001), and four additional ones, 1p31 (p = 0.005) for asthma, 11q13 (p = 0.006) for IgE, 13q31 (p = 0.001) for eosinophils, and 19q13 (p = 0.02) for BR...
  55. ncbi request reprint Epigenetic inheritance of fetal genes in allergic asthma
    J Bousquet
    Department of Respiratory Diseases, University Hospital, Montpellier, France INSERM U454, Montpellier, France
    Allergy 59:138-47. 2004
    ..Clear delineation of these issues may yield new information on the mechanisms of asthma and new targets for therapeutic intervention and primary prevention...
  56. ncbi request reprint [Asthma and rhinitis medications: pregnancy precautions]
    P Demoly
    INSERM U454, IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier
    Presse Med 29:1625-9. 2000
    ..Indeed, it would be regrettable to be too prudent and deprive symptomatic patients of active treatments. Patients should be clearly informed of the benefits and risks of drug therapy...
  57. ncbi request reprint Anaphylaxis to antitetanus toxoid serum
    P Demoly
    Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5, France
    Allergy 57:860-1. 2002
  58. doi request reprint Prioritised research agenda for prevention and control of chronic respiratory diseases
    J Bousquet
    Service des Maladies Respiratories Hopital Arnaud De Villeneuve, 34295 Montpellier Cedex 5, France
    Eur Respir J 36:995-1001. 2010
    ..This requires both CRD-targeted interventions and transverse NCD programmes which include CRDs, with emphasis on health promotion and disease prevention...
  59. doi request reprint Heterogeneity of asthma according to blood inflammatory patterns
    R Nadif
    Institut National de la Sante et de la Recherche Medicale, Villejuif, France
    Thorax 64:374-80. 2009
    ..There is increasing interest regarding asthma heterogeneity in relation to inflammatory patterns...
  60. pmc Air pollution and asthma severity in adults
    E Rage
    INSERM U780, 16 Avenue Paul Vaillant Couturier, Villejuif Cedex, France
    Occup Environ Med 66:182-8. 2009
    ..The aim was to assess the relation between asthma severity during the past 12 months and home outdoor concentrations of air pollution...
  61. pmc Rapid non-genomic inhibition of ATP-induced Cl- secretion by dexamethasone in human bronchial epithelium
    V Urbach
    INSERM U454, CHU A de Villeneuve, 34295 Montpellier cedex 05, France
    J Physiol 545:869-78. 2002
    ..Rather, it is a result of rapid non-genomic stimulation of thapsigargin-sensitive Ca(2+)-ATPase, via adenylate cyclase and protein kinase A signalling...
  62. ncbi request reprint Increased bronchoalveolar lavage CD8 lymphocyte subset population in wheezy infants
    B Arnoux
    INSERM U454 IFR3, Hopital Arnaud de Villeneuve, 34295 Montpellier Cedex 5, France
    Pediatr Allergy Immunol 12:194-200. 2001
    ..The results of the present study suggest that viral infection may have induced a CD8(+) response in BAL cells...
  63. ncbi request reprint Eosinophilic inflammation in sputum of poorly controlled asthmatics
    M Romagnoli
    Clinique des Maladies Respiratoires, Institut National de la Santé et de la Recherche Médicale U454, Centre Hospitalier Universitaire Montpellier, Hopital Arnaud de Villeneuve, Montpellier, France
    Eur Respir J 20:1370-7. 2002
    ..These results suggest that sputum eosinophilia is associated with poorly controlled asthma rather than with the severity of asthma...
  64. doi request reprint Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper
    J Bousquet
    University Hospital and INSERM, Montpellier, France
    Allergy 63:842-53. 2008
    ..It is likely that neuronal mechanisms, T cells, innate immunity and possibly auto-immune responses all play a role in NAR and may also contribute to the symptoms of allergic rhinitis...
  65. ncbi request reprint [Corticosteroid therapy of asthma]
    P Chanez
    Clinique des Maladies Respiratoires, CHU de Montpellier
    Presse Med 29:1469-78. 2000
    ..Glucocorticoids are the gold standard treatment in asthma affecting most of the components involved in bronchial inflammation. Inhaled steroids are recommended early in most countries...
  66. ncbi request reprint [Epidemiological study on the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy (EGEA) - First results of a multi-disciplinary study]
    F Kauffmann
    INSERM U 472, Villejuif, France
    Rev Mal Respir 19:63-72. 2002
    ..The analysis is still in progress by studies on the heterogeneity of asthma with refined genetic studies and by searching to integrate results regarding environmental and genetic factors and studying their interactions...
  67. ncbi request reprint Predicting and evaluating response to omalizumab in patients with severe allergic asthma
    J Bousquet
    Service de Pneumologie, Hopital Arnaud de Villeneuve, 371 Avenue du Doyen G Giraud, Montpellier 34295, France
    Respir Med 101:1483-92. 2007
    ..Omalizumab is a monoclonal antibody indicated for treatment of severe persistent allergic asthma inadequately controlled despite optimal controller therapy. We investigated whether patient selection could be targeted further...
  68. ncbi request reprint [Genetics of asthma and atopy]
    P Demoly
    Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, CHU de Montpellier
    J Soc Biol 194:39-42. 2000
    ..Much of the information available today has been fragmentary and not always confirmed. Alleles at multiple loci are likely to be involved and the ultimate picture is most likely determined by many genetic and environmental factors...
  69. ncbi request reprint Epidemiology of drug allergy
    P Demoly
    Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
    Curr Opin Allergy Clin Immunol 1:305-10. 2001
    ..Therefore, there are few true epidemiological data, and most of those that are available, including incidence, mortality and socioeconomic impact data, should be interpreted with caution...
  70. doi request reprint Randomized controlled trial of desloratadine for persistent allergic rhinitis: correlations between symptom improvement and quality of life
    Jean Bousquet
    Hopital Arnaud de Villeneuve, Montpellier, France
    Allergy Asthma Proc 34:274-82. 2013
    ..Continuous daily treatment of moderate-to-severe PER with desloratadine at 5 mg/day significantly improved symptoms, which correlated positively, albeit moderately, with QOL benefits and reversal of functional impairments caused by PER...
  71. doi request reprint Inhaled corticosteroid/long-acting β₂-agonist combination therapy for asthma: attitudes of specialists in Europe
    Jean Bousquet
    Clinic for Respiratory Diseases, Hopital Arnaud de Villeneuve, Montpellier, France
    Int Arch Allergy Immunol 157:303-10. 2012
    ..The aim of this study was to assess which attributes of combination therapy physicians consider most important...
  72. doi request reprint Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma
    Jean Bousquet
    University Hospital, Hopital Arnaud de Villeneuve, Montpellier, France
    J Allergy Clin Immunol 126:926-38. 2010
    ..The last group includes asthma for which control is not achieved despite the highest level of recommended treatment and asthma for which control can be maintained only with the highest level of recommended treatment...
  73. ncbi request reprint Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction
    Djamel Messaad
    Hopital Arnaud de Villeneuve, Montpellier, France
    Ann Intern Med 140:1001-6. 2004
    ..Drug hypersensitivity reactions are common and can be life-threatening. Confirmation of the diagnosis should be rigorous and based on clinical history and a physical examination, possibly followed by skin tests and drug provocation tests...
  74. ncbi request reprint Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project
    J Bousquet
    Service des Maladies Respiratoires, University Hospital, Montpellier, France
    Allergy 61:671-80. 2006
    ....
  75. ncbi request reprint Validation of the classification of ARIA (allergic rhinitis and its impact on asthma)
    P Demoly
    Unité d Explorations des Allergies, Service des Maladies Respiratoires, INSERM, Hopital Arnaud de Villeneuve, Montpellier Cedex, France
    Allergy 58:672-5. 2003
    ..Allergic rhinitis is commonly divided into seasonal and perennial rhinitis. The recent Allergic Rhinitis and its Impact on Asthma (ARIA) workshop proposes to replace these terms by intermittent vs persistent rhinitis...
  76. ncbi request reprint A comparison of topical mequitazine and disodium cromoglycate in allergic conjunctivitis induced by a specific conjunctival provocation test
    O Dupin
    Laboratoire Chauvin, Montpellier, France
    Eur J Ophthalmol 10:15-21. 2000
    ..Twenty-two people with a history of grass pollen allergic conjunctivitis were enrolled outside the pollen season in this study to compare the efficacy of 0.05% mequitazine eyedrops with topical 2% disodium cromoglycate...
  77. doi request reprint GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic'
    J Bousquet
    University Hospital and INSERM U780, Hopital Arnaud de Villeneuve, Montpellier, France
    Allergy 64:969-77. 2009
    ..The major achievements of GA(2)LEN are reported in this paper...
  78. doi request reprint Allergic rhinitis management pocket reference 2008
    J Bousquet
    Allergic Rhinitis and its Impact on Asthma, Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, 34295 Montpellier Cedex 5, France
    Allergy 63:990-6. 2008
    ..This document will be a major resource in this educational program...
  79. ncbi request reprint Conclusion. Nebulized beclometasone dipropionate therapy in asthma
    J Bousquet
    Hôpital Arnaud deVilleneuve, Montpellier, France
    Respir Med 97:S41. 2003
  80. ncbi request reprint Introduction. Nebulized beclometasone dipropionate therapy in asthma
    J Bousquet
    Hopital Arnaud de Villeneuve, Montpellier, France
    Respir Med 97:S1-4. 2003
  81. ncbi request reprint The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma
    J Bousquet
    Hopital Arnaud de Villeneuve, Montpellier, France
    Allergy 60:302-8. 2005
    ..Such patients are at high risk of serious exacerbations and asthma-related mortality...
  82. ncbi request reprint Basophil activation during pollen season in patients monosensitized to grass pollens
    M Saporta
    INSERM U454-IFR3, Montpellier, France
    Allergy 56:442-5. 2001
    ..CONCLUSION: Basotest can therefore be used as a diagnostic test during the pollen season, but the allergen exposure needs to be characterized if quantitative studies are performed...
  83. doi request reprint Pooling birth cohorts in allergy and asthma: European Union-funded initiatives - a MeDALL, CHICOS, ENRIECO, and GA²LEN joint paper
    Jean Bousquet
    University Hospital, Hopital Arnaud de Villeneuve, Montpellier, France
    Int Arch Allergy Immunol 161:1-10. 2013
    ..The aim of this paper is to review current and past EU-funded projects in order to make a summary of their goals and achievements and to suggest future research needs of these European birth cohort networks...
  84. ncbi request reprint Severity and impairment of allergic rhinitis in patients consulting in primary care
    Jean Bousquet
    University Hospital and Institut National de la Santé et de la Recherche Médicale U454, Montpellier, France
    J Allergy Clin Immunol 117:158-62. 2006
    ..Allergic rhinitis is a disease impairing quality of life, sleep, and work. A new classification for allergic rhinitis, Allergic Rhinitis and its Impact on Asthma (ARIA), has recently been proposed...
  85. ncbi request reprint Allergen immunotherapy: therapeutic vaccines for asthma
    Jean Bousquet
    Montpellier University, Montpellier, France
    Clin Allergy Immunol 18:511-28. 2004
  86. ncbi request reprint Allergy and asthma: from the bedside to the bench and international actions
    Jean Bousquet
    Service des Maladies Respiratoires, INSERM, Hopital Arnaud de Villeneuve, Montpellier Cedex 05, France
    Pol Arch Med Wewn 118:363-6. 2008
    ..From research, public health programs can be designed...
  87. doi request reprint Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
    J Bousquet
    University Hospital and INSERM, Hopital Arnaud de Villeneuve, Montpellier, France
    Allergy 63:8-160. 2008
  88. ncbi request reprint Introduction. Modulite: simplifying the changeover
    J Bousquet
    Hopital Arnaud de Villeneuve, Montpellier, France
    Respir Med 96:S1-2. 2002
  89. ncbi request reprint Prick tests to aeroallergens: is it possible simply to wipe the device between tests?
    V Piette
    Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, France
    Allergy 57:940-2. 2002
    ....
  90. ncbi request reprint Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial
    J Bousquet
    Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier, France
    Allergy 58:733-41. 2003
    ..However, their efficacy has never been tested. The aim of the study was to validate the guidelines of the International Consensus on Rhinitis in the treatment of seasonal allergic rhinitis...
  91. ncbi request reprint Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines
    P J Bousquet
    University Hospital and INSERM U454, Montpellier, France
    Allergy 62:367-72. 2007
    ..The allergic rhinitis and its impact on asthma (ARIA) guidelines provide a new classification of allergic rhinitis, but a quantitative analysis for severity assessment is lacking...
  92. doi request reprint Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study
    J Bousquet
    Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier, France
    Allergy 64:1516-23. 2009
    ..There is no placebo-controlled, randomized clinical trial on intermittent allergic rhinitis (IAR) to date. Desloratadine (DL) is recommended for the first-line treatment of seasonal and perennial allergic rhinitis...
  93. ncbi request reprint Rhinosinusitis in severe asthma
    M Bresciani
    Service des Maladies Respiratoires and INSERM U 454, , CHU de Montpellier, Montpellier, France
    J Allergy Clin Immunol 107:73-80. 2001
    ....
  94. ncbi request reprint Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils
    V Kvedariene
    INSERM U454 IFR3, Hopital Arnaud de Villeneuve, Montpellier Cedex, France
    Allergy 61:311-5. 2006
    ..Basophil activation based upon the expression of CD63 in the presence of specific allergens was found to be of importance for the diagnosis of IgE-mediated hypersensibility...
  95. ncbi request reprint Modulation of eicosanoid and histamine release from human dispersed lung cells by terfenadine
    A M Campbell
    Clinique des Maladies Respiratoires, Centre Hospitalier Universitaire, Montpellier, France
    Allergy 48:125-9. 1993
    ..Terfenadine inhibits, in a dose-dependent manner, the release of eicosanoids after challenge of dispersed lung cells by anti-IgE, and this effect may have some clinical relevance...
  96. ncbi request reprint A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma
    Jean Bousquet
    Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Centre Hospitalier Universitaire Montpellier, France
    Clin Ther 24:1-20. 2002
    ..Although inhaled corticosteroids (ICS) are commonly used in the treatment of persistent asthma, the relationship between dose and clinical response remains unclear...
  97. ncbi request reprint Allergic rhinitis: a disease remodeling the upper airways?
    Jean Bousquet
    Clinique des Maladies Respiratoires, University Hospital and INSERM U454, Montpellier, France
    J Allergy Clin Immunol 113:43-9. 2004
    ..A better understanding of nasal and bronchial remodeling might help to identify new pathways and new therapeutic strategies to reduce long-term remodeling in asthma...
  98. ncbi request reprint Primary and secondary prevention of allergy and asthma by allergen therapeutic vaccines
    Jean Bousquet
    Montpellier University, Montpellier, France
    Clin Allergy Immunol 18:105-14. 2004
  99. ncbi request reprint Modulation of cadherin and catenins expression by tumor necrosis factor-alpha and dexamethasone in human bronchial epithelial cells
    Nathalie Carayol
    Clinique des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier, France
    Am J Respir Cell Mol Biol 26:341-7. 2002
    ..We demonstrated, using Western blot analysis and immunofluorescence, that proinflammatory cytokines could be responsible for structural damage to the epithelium and that this process was potentially reversed by steroids...
  100. ncbi request reprint Prevention of recurrent respiratory tract infections in children using a ribosomal immunotherapeutic agent: a clinical review
    Jean Bousquet
    Respiratory Diseases Department, A de Villeneuve Hospital, Montpellier, France
    Paediatr Drugs 8:235-43. 2006
    ..Ribomunyl also decreased absence from work or school, which has important economic consequences...
  101. ncbi request reprint [Identifying and understanding drug allergies]
    Pascal Demoly
    Inserm U 454 IFR3, Hopital Arnaud de Villeneuve, Avenue Gaston Giraud, 34295 Montpellier, France
    Med Sci (Paris) 19:327-36. 2003
    ....